Coronary Thrombosis in a Patient with COVID-19 Who Was on Anticoagulant Therapy

authors:

avatar Mohammad Reza Hatamnejad ORCID 1 , avatar Farima Fallah Tafti 1 , avatar Ali Abdi ardekani 2 , avatar Shahrokh Sadeghi Boogar ORCID 3 , avatar Hamed Bazrafshan Drissi ORCID 2 , *

Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Department of Internal Medicine, Shiraz University of Medical Science, Shiraz, IR Iran
International Cardiovascular Research Journal: Vol.15, issue 3; e114520
published online: September 01, 2021
article type: Case Report
received: March 09, 2021
accepted: July 06, 2021

how to cite: Hatamnejad M R, Fallah Tafti F, Abdi ardekani A, Sadeghi Boogar S, Bazrafshan Drissi H. Coronary Thrombosis in a Patient with COVID-19 Who Was on Anticoagulant Therapy. Int Cardiovasc Res J. 2021;15(3):e114520. 

Abstract

Introduction: COVID-19-related thrombotic events are associated with an increase in the risk of mortality and morbidity. Considering the research on the pathophysiology of the disease, the significance of cardiac thrombosis is being more recognized.
Case Presentation: This study aimed to present the first case report of a Left Main Coronary Artery (LMCA) thrombosis due to COVID-19 infection in a middle-aged male with a mechanical valve on anticoagulant therapy and with an International Normalized Ratio (INR) within the therapeutic range.
Conclusions: The results suggested that the therapeutic INR range may need to be higher (about 3.5) during the acute phase of COVID-19 infection to prevent thrombotic events amongst patients with COVID-19 who are on anticoagulant therapy. However, further evidence is required to determine the target range for INR in patients with COVID-19 who are on anticoagulants prior to infection.
 

Fulltext

The full-text is available in pdf.

References

  • 1.

    The references are available in pdf.